Poltreg SA
WSE:PTG
Poltreg SA
PolTREG SA develops and commercializes patented TREG methods. The company is headquartered in Gdansk, Woj. Pomorskie and currently employs 11 full-time employees. The company went IPO on 2021-11-23. The firm conducts research in the field of autoimmunological diseases. The firm works on a method of healing, that uses t-regulated cells (TREGs). The Firm possesses its own, patented technology to obtain T-regulated lymphocytes, that are used in the therapy. The firm works on therapy for diseases such as type one diabetes, type two diabetes, and multiple sclerosis. In its research, the Company cooperates with multiple specialists from various fields of science. The firm is developing its own research center, which is intended as a basic location for conducting future research activities.
PolTREG SA develops and commercializes patented TREG methods. The company is headquartered in Gdansk, Woj. Pomorskie and currently employs 11 full-time employees. The company went IPO on 2021-11-23. The firm conducts research in the field of autoimmunological diseases. The firm works on a method of healing, that uses t-regulated cells (TREGs). The Firm possesses its own, patented technology to obtain T-regulated lymphocytes, that are used in the therapy. The firm works on therapy for diseases such as type one diabetes, type two diabetes, and multiple sclerosis. In its research, the Company cooperates with multiple specialists from various fields of science. The firm is developing its own research center, which is intended as a basic location for conducting future research activities.
